Impurities in Oligonucleotide Drug Substances and Drug Products

被引:85
作者
Capaldi, Daniel [1 ]
Teasdale, Andy [2 ]
Henry, Scott [1 ]
Akhtar, Nadim [2 ]
den Besten, Cathaline [3 ]
Gao-Sheridan, Samantha [4 ]
Kretschmer, Matthias [4 ]
Sharpe, Neal [5 ]
Andrews, Ben [6 ]
Burm, Brigitte [7 ]
Foy, Jeffrey [8 ]
机构
[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA
[2] AstraZeneca UK Ltd, Macclesfield, Cheshire, England
[3] ProQR Therapeut NV, Leiden, Netherlands
[4] Alnylam Pharmaceut Inc, Cambridge, MA USA
[5] Anavex Life Sci Corp, New York, NY USA
[6] GlaxoSmithKline, Stevenage, Herts, England
[7] ISA Therapeut, Leiden, Netherlands
[8] Celgene Corp, Summit, NJ USA
关键词
oligonucleotides; impurities; identification; qualification; PERFORMANCE LIQUID-CHROMATOGRAPHY; CAPILLARY GEL-ELECTROPHORESIS; IONIZATION MASS-SPECTROMETRY; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; INTERFERING RNA; NUCLEIC-ACIDS; THERAPEUTICS; DNA; RECOMMENDATIONS; OLIGODEOXYNUCLEOTIDES;
D O I
10.1089/nat.2017.0691
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This white paper, which is the 10th in a series intended to address issues associated with the development of therapeutic oligonucleotides, examines the subject of product-related impurities. The authors consider chemistry and safety aspects and advance arguments in favor of platform approaches to impurity identification and qualification. Reporting, identification, and qualification thresholds suitable for product-related impurities of therapeutic oligonucleotides are proposed.
引用
收藏
页码:309 / 322
页数:14
相关论文
共 55 条
[1]   Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations [J].
Alton, Eric W. ;
Boushey, Homer A. ;
Garn, Holger ;
Green, Francis H. ;
Hodges, Michael ;
Martin, Richard J. ;
Murdoch, Robert D. ;
Renz, Harald ;
Shrewsbury, Stephen B. ;
Seguin, Rosanne ;
Johnson, Graham ;
Parry, Joel D. ;
Tepper, Jeff ;
Renzi, Paolo ;
Cavagnaro, Joy ;
Ferrari, Nicolay .
NUCLEIC ACID THERAPEUTICS, 2012, 22 (04) :246-254
[2]   Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry [J].
Apffel, A ;
Chakel, JA ;
Fischer, S ;
Lichtenwalter, K ;
Hancock, WS .
ANALYTICAL CHEMISTRY, 1997, 69 (07) :1320-1325
[3]   SEPARATION OF SYNTHETIC PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES FROM THEIR OXYGENATED (PHOSPHODIESTER) DEFECT SPECIES BY STRONG-ANION-EXCHANGE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BERGOT, BJ ;
EGAN, W .
JOURNAL OF CHROMATOGRAPHY, 1992, 599 (1-2) :35-42
[4]   OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics [J].
Berman, Cindy L. ;
Barros, Scott A. ;
Galloway, Sheila M. ;
Kasper, Peter ;
Oleson, Frederick B. ;
Priestley, Catherine C. ;
Sweder, Kevin S. ;
Schlosser, Michael J. ;
Sobol, Zhanna .
NUCLEIC ACID THERAPEUTICS, 2016, 26 (02) :73-85
[5]   Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics [J].
Berman, Cindy L. ;
Cannon, Keri ;
Cui, Yi ;
Kornbrust, Douglas J. ;
Lagrutta, Armando ;
Sun, Sunny Z. ;
Tepper, Jeff ;
Waldron, Gareth ;
Younis, Husam S. .
NUCLEIC ACID THERAPEUTICS, 2014, 24 (04) :291-301
[6]   Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex [J].
Beverly, M ;
Hartsough, K ;
Machemer, L ;
Pavco, P ;
Lockridge, J .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 835 (1-2) :62-70
[7]  
Bonilla JV., 2011, Handbook of Analysis of Oligonucleotides and Related Products
[8]   LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY OF ANTISENSE OLIGONUCLEOTIDES [J].
BOTHNER, B ;
CHATMAN, K ;
SARKISIAN, M ;
SIUZDAK, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (23) :2863-2868
[9]   Chemistry at the 2′ Position of Constituent Nucleotides Controls Degradation Pathways of Highly Modified Oligonucleotide Molecules [J].
Calvitt, C. Jeffrey ;
Levin, Daren S. ;
Shepperd, Benjamin T. ;
Gruenloh, Christopher J. .
OLIGONUCLEOTIDES, 2010, 20 (05) :239-251
[10]  
Capaldi D. C., 2008, ANTISENSE DRUG TECHN, P401